CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia

Ekaterina Chelysheva,Anna Petrova,Margarita Gurianova,Oleg Shukhov,Anastasia Bykova,Irina Nemchenko,Dmitry Tikhomirov,Hunan Julhakyan,Alina Kokhno,Anna Turkina

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览9

暂无评分

摘要

Sputnik V vaccine showed no unexpected or severe AEs in CML patients. Seroconversion rate of about 93-94% was close to the 3-phase trial data (94-97%). No strong age-dependent/time-dependent correlation of antibody levels was found in the tested time period. Sputnik V vaccination is safe and acceptable in CML patients.

查看译文

关键词

CML,chronic myeloid leukemia,COVID-19,vaccination,vaccine,SARS-CoV-2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要